NASDAQ:AMBI - Ambit Biosciences Stock Price, News, & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Sign in or create an account to add this stock to your watchlist.
$0.30 0.00 (0.00 %)
(As of 12/4/2018)
Previous Close$0.30
Today's Range$0.30 - $0.30
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Receive AMBI News and Ratings via Email

Sign-up to receive the latest news and ratings for AMBI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:AMBI



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Ambit Biosciences (NASDAQ:AMBI) Frequently Asked Questions

What is Ambit Biosciences' stock symbol?

Ambit Biosciences trades on the NASDAQ under the ticker symbol "AMBI."

How were Ambit Biosciences' earnings last quarter?

Ambit Biosciences Corp (NASDAQ:AMBI) released its quarterly earnings data on Tuesday, May, 6th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.03. The biopharmaceutical company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $3.50 million. View Ambit Biosciences' Earnings History.

Has Ambit Biosciences been receiving favorable news coverage?

Press coverage about AMBI stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ambit Biosciences earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term.

What other stocks do shareholders of Ambit Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ambit Biosciences investors own include Alexion Pharmaceuticals (ALXN), Amarin (AMRN), Broadcom (BRCM), Cytokinetics (CYTK), Fortress Biotech (FBIO), FireEye (FEYE), Five Prime Therapeutics (FPRX), Glu Mobile (GLUU), Halozyme Therapeutics (HALO) and Immunomedics (IMMU).

What is Ambit Biosciences' stock price today?

One share of AMBI stock can currently be purchased for approximately $0.30.

How can I contact Ambit Biosciences?

Ambit Biosciences' mailing address is 11080 Roselle St, SAN DIEGO, CA 92121-1233, United States. The biopharmaceutical company can be reached via phone at +1-858-3342100.

MarketBeat Community Rating for Ambit Biosciences (NASDAQ AMBI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  156
MarketBeat's community ratings are surveys of what our community members think about Ambit Biosciences and other stocks. Vote "Outperform" if you believe AMBI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMBI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel